Psoriatic arthritis

‘Window of opportunity’: TNFi induce high rates of remission in early SpA

Early use of anti‐TNF treatment in peripheral spondyloarthritis (pSpA) can achieve sustained drug-free clinical remission in more than 50% of patients, a European study has shown. In a trial that backs the “window of opportunity” hypothesis for treatment of the very early stages of pSpA, patients whose treatment with golimumab was started within 12 weeks ...

Already a member?

Login to keep reading.

© 2021 the limbic